Takeda presents HIJ-Create study results

Takeda has announced the results of the Heart Institute of Japan-Candesartan Randomised trial for Evaluation in Coronary Artery Disease (HIJ-Create) study at the scientific session of the American Heart Association held in Miami.

Results from the HIJ-Create trials showed that patients administered with Blopress exhibited an 11 per cent reduction in major adverse cardiovascular events (Mace) compared to non-angiotensin receptor blocker standard therapy, though statistical significance was not shown.

In patients with impaired renal function, Blopress showed a 21 per cent reduction in the incidence of Mace compared to non-angiotensin receptor locker standard therapy.

Hiroshi Kasanuki, chief professor of the department of cardiology at the Graduate School of Medicine at Tokyo Women’s Medical University, said: “Blopress therapy may reduce the incidence of Mace in patients with impaired renal function in addition to reduction of new onset of diabetes mellitus.”

He added that despite the lack of statistical significance in the primary endpoint of the trial, the study saw fewer drug-related adverse events with Blopress therapy, while the results were substantive in their highlighting of the importance of organ protection through the suppression of the renin-angiotensin system.

In August 2007, Takeda announced that Blopress, also known as TAK-536, had entered phase II of clinical trials as a treatment for hypertension.